Elasnin Effectively Eradicates Daptomycin-Resistant Methicillin-Resistant Staphylococcus aureus Biofilms

Area of Science:

• Microbiology
• Infectious Diseases
• Drug Discovery

Background:

• Daptomycin-resistant methicillin-resistant Staphylococcus aureus (MRSA) strains are emerging due to increased daptomycin use.
• Biofilm formation by MRSA complicates treatment and contributes to persistent infections.

Purpose of the Study:

• To evaluate the antibiofilm efficacy of elasnin against daptomycin-resistant MRSA.
• To investigate the underlying mechanisms for elasnin's activity against resistant strains.

Main Methods:

• Minimum biofilm eradication concentration (MBEC) assays were performed.
• Confocal microscopy was used to assess biofilm eradication.
• Quantitative proteomics was employed to analyze protein expression differences.

Main Results:

• Elasnin demonstrated superior biofilm eradication against daptomycin-resistant MRSA (MBEC 0.625 μg/mL) compared to wild-type (MBEC 2.5 μg/mL).
• Confocal microscopy showed a ~53% decrease in cell density for resistant strains versus ~15% for wild-type strains after elasnin treatment.
• Proteomics revealed lower expression of membrane, cell wall, extracellular, and pathogenesis-related proteins in the resistant strain.

Conclusions:

• Elasnin exhibits significant potential for clinical application against daptomycin-resistant MRSA biofilms.
• The superior activity of elasnin is linked to the reduced expression of proteins involved in biofilm formation in resistant strains.
• This study provides mechanistic insights into elasnin's antibiofilm action and its effectiveness against challenging MRSA infections.